There is hope on the horizon for Lupus patients. A new multi-year clinical trial has commenced, testing whether a type of ...

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

Subacute cutaneous lupus erythematosus (SCLE), an autoimmune-mediated disease that is characterized by widespread hardening of the skin, is triggered by various environmental factors, including ...

This is to be expected, as only IgG can cross the placenta from the mother. Adults with subacute cutaneous lupus erythematosus will have IgG and IgM deposits on IF of skin lesions (Lee ...

Specific and nonspecific rashes associated with antibodies to Ro/SS-A are often related to subacute cutaneous lupus erythematosus ... including history, treatment, patient education, and nursing ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) ...

Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...